![]() |
|
|
March 2008 |
|
To view past issues of the Securities Update, please visit http://business.cch.com/updates/securities If you have questions or comments concerning the information provided below, please contact me at elena.eyber@wolterskluwer.com. CCH Federal Securities Law Reporter
Smaller Company Auditor Attestation
Requirement Extension Proposed
SEC Proposes Amendments Affecting Foreign
Private Issuers
Southern District of New York Rejects
Selective Privilege Waiver The company's general counsel began an internal investigation into alleged misconduct concerning the allocation of shares in IPOs, and the company employed outside counsel to interview employees and prepare written summaries of their investigation. Credit Suisse disclosed the documents to the U.S. Attorney and the SEC pursuant to confidentiality agreements. Documents were also discussed with officers of NASDR and disclosed to some former employees in an arbitration proceeding. The court initially found that the documents did qualify as "fact" work product, such as investigative data, which is generally afforded a lower level of protection than "legal" work product, including analysis and legal theories. However, the court found that Credit Suisse had waived any such privilege. Judge Scheindlin found the company's claim that it shared "common interests" with the U.S. Attorneys and the SEC to be "baseless," as the government entities were investigating potential wrongdoing and "Credit Suisse disclosed the Memoranda to escape or limit liability." In addition, the mere fact that a confidentiality agreement existed did not establish the disclosures as a selective waiver, and the company showed no special circumstances to negate a waiver finding. Judge Scheindlin concluded that "[a]ny confidentiality that may have existed between Credit Suisse and its attorneys has been abandoned." According to the court, "[p]rotection of the Memorandum would serve Credit Suisse's strategic purposes, not any societal interest in fostering communications between attorneys and their clients." In re Initial Public Offering Securities Litigation (SD NY) is reported at ¶94,580 (ip access user). "Strong Inference" Standard
Applied to Section 14(a) Negligence Claims The court found that Tellabs raised the pleading standards for scienter in the 10th Circuit, so it was appropriate to re-examine the allegations in the complaint. Initially, the court stated that the standard for pleading scienter laid out in the 10th Circuit in Pirraglia v. Novell, Inc. (2002-2003 CCH Dec. ¶92,478 (ip access user)) was "substantially similar" to the standard adopted by the Supreme Court in Tellabs, as the court held that all reasonable inferences to be drawn from the allegations, including inferences unfavorable to the plaintiffs, must be considered. According to the district court, this 10th Circuit precedent "clearly required long before Tellabs that a district court engage in a comparative evaluation of all inferences to be drawn from the complaint" and "the 10th Circuit accurately predicted the holding in Tellabs by awarding the draw to the plaintiff when there are equally strong inferences for and against scienter." However, the district court concluded that "Pirraglia leaves open the possibility that an inference of scienter could be deemed sufficiently "strong" to survive a motion to dismiss even if an innocent inference tips the scales ever so slightly," which "would be a result that is impermissible under Tellabs." Because Tellabs raised the pleading standard for scienter, it was appropriate for the court to reconsider the allegations in the amended complaint. Upon re-examination, the allegations were found to be sufficient to permit a reasonable person to draw an inference of scienter that was cogent and at least as compelling as any opposing inference. Next, while the court found that the shareholders' proxy claims were pleaded in negligence and did not sound in fraud, the "strong inference" pleading standard articulated in Tellabs was applied. The court held that Tellabs is not limited to cases in which the state of mind is scienter. In this case, the shareholders adequately pleaded with particularity facts giving rise to a strong inference of negligence. State of New Jersey v. Sprint Corp. (DC Kan) is reported at ¶94,576 (ip access user). CCH Blue Sky Law Reporter
Indiana Recognizes Toronto Stock Exchange
As Approved Exchange
Iowa Amends Investment Adviser Financial
Reporting and Minimum Net Capital Requirements
Court Declines to Enjoin Order Sanctioning
Hedge Fund Communications
New Smart Chart Added: Registration
Requirements for Agents of Broker-Dealers
New Smart Chart Added: Registration
of Securities Aspen Federal Securities Publications
Broker-Dealer Law and Regulation, Fourth
Edition, by Norman S. Poser and James A. Fanto
EDGAR Filer Handbook, by Charles H.
Rider Hot Topic of the Month
This month's hot topic is attorney-client privilege. The waiver of attorney-client privilege in connection with enforcement actions has been the subject of ongoing debate. SEC Commissioner Paul Atkins recently noted that the SEC is re-examining its policies and procedures with respect to the practice of requiring companies to waive their attorney-client protections as a condition of receiving credit for cooperating with SEC investigations. The American Bar Association has urged the Commission to stop the practice, and legislation is currently pending which would stop the SEC and other federal agencies from conditioning a company's cooperative efforts on waiving the attorney-client and work privileges. In a letter to the SEC, the ABA said that it believes that current policies contribute to what it called a "culture of waiver" that could lead to "profoundly negative consequences." In particular, the ABA asked the SEC to revise its Seaboard report which outlines the factors the SEC will consider when deciding whether to grant credit for cooperation. In the ABA's view, the policies set forth by the SEC contain language that could erode the protection afforded by the attorney-client privilege. In practice, the ABA said, companies have no choice but to waive the privilege when encouraged or requested to do so because the risk of being labeled uncooperative will have a great effect not just on the Commission's enforcement action decisions, but also on the company's image and stock price. The House has already passed H.R. 3013, the Attorney-Client Privilege Protection Act, and a companion bill in the Senate, S.186, is in committee. These bills prohibit federal agencies from pressuring companies to waive their privileges or from taking punitive actions against their employees as conditions to receiving cooperation credit during investigations. The bills specifically preserve the ability of prosecutors and other federal officials to obtain the important nonprivileged factual material they need to punish wrongdoers. We publish related information in a wide range of resources (e.g., Federal Securities Law Reporter, SEC Today, Insights – Amy L. Goodman, Securities Regulation – Loss, Seligman & Paredes, etc.), and document types (laws, regulations, releases, newsletter articles, treatise discussion). For example: SEC Today
Federal Securities Law Reporter
SEC Docket
Insights – Amy L. Goodman
(e.g., “Attorney-Client Privilege and Work Product Doctrine in Government
Investigations” (June
2007) (ip
access user) IPO Vital Signs
IPO Vital Signs, an advanced IPO research analysis tool, assists IPO professionals and pre-IPO companies satisfy their most challenging research needs and answers hundreds of mission critical questions for all the players in the IPO process. IPO Vital Signs’ tabular data analyses focus on issues surrounding client advisement, deal negotiation, and prospectus disclosure. IPO Week in Review, a weekly e-newsletter to keep professionals up to date with recent filing and going public activity, is an important element of the IPO Vital Signs system or is available by separate subscription. Coverage includes a monthly feature article on recent trends in going public in the U.S. To see how an IPO Vital Sign works click on the Vital Sign title below: Use IPO Vital Sign #324 to…
|